Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
2007-11-26
2009-06-02
Shiao, Rei-Tsang (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
C514S562000, C514S604000, C514S605000, C562S430000, C564S083000, C564S092000, C564S097000, C564S099000
Reexamination Certificate
active
07541383
ABSTRACT:
Compounds, pharmaceutical compositions and methods are provided that are useful in the treatment of inflammatory and immune-related diseases and conditions. In particular, the invention provides compounds which modulate the function and/or expression of proteins involved in atopic diseases, inflammatory conditions and cancer. The subject compounds are carboxylic acid derivatives.
REFERENCES:
patent: 5545669 (1996-08-01), Adams et al.
patent: 5962682 (1999-10-01), Breu et al.
patent: 6008234 (1999-12-01), Kochanny et al.
patent: 6133442 (2000-10-01), Breu et al.
patent: 6531291 (2003-03-01), Kabbash et al.
patent: 2002/0022218 (2002-02-01), Li et al.
patent: 0284202 (1988-09-01), None
patent: 0930528 (1999-07-01), None
patent: 0947500 (1999-10-01), None
patent: 1170594 (2002-01-01), None
patent: 2 388 540 (2003-11-01), None
patent: WO 95/01326 (1995-01-01), None
patent: WO 95/33461 (1995-12-01), None
patent: WO 96/19455 (1996-06-01), None
patent: WO 98/11094 (1998-03-01), None
patent: WO 99/55663 (1999-11-01), None
patent: WO 00/17204 (2000-03-01), None
patent: WO 00/40561 (2000-07-01), None
patent: WO 00/53573 (2000-09-01), None
patent: WO 01/14882 (2001-03-01), None
patent: WO 01/79169 (2001-10-01), None
patent: WO 01/94309 (2001-12-01), None
patent: WO 02/45718 (2002-06-01), None
patent: WO 02/094830 (2002-11-01), None
patent: WO 03/016254 (2003-02-01), None
patent: WO 03/066046 (2003-08-01), None
patent: WO 03/066047 (2003-08-01), None
patent: WO 03/078409 (2003-09-01), None
patent: WO 03/097042 (2003-11-01), None
patent: WO 03/097598 (2003-11-01), None
patent: WO 03/101961 (2003-12-01), None
patent: WO 03/101981 (2003-12-01), None
Cosmi et al., “Chemoattractant Receptors Expressed on Type 3 T Cells and Their Role in Disease,” Int. Arch. Allergy Immunol., 125:273-279 (2001).
Fujitani et al., “Pronounced Eosinophilic Lung Inflammation and Th2 Cytokine Release in Human Lipocalin-Type Prostaglandin D Synthase Transgenic Mice,” J. Immunol., 168:443-449 (2002).
Hirai et al., “Prostaglandin D2 Selectively Induces Chemotaxis in T Helper Type 2 Cells, Eosinophils, and Basophils via Seven-Transmembrane Receptor CRTH2,” J. Exp. Med., 193(2):255-261 (2001).
Iwasaki et al., “Association of a New-Type Prostaglandin D2 Receptor CRTH2 with Circulating T Helper 2 Cells in Patients with Atoipic Dermatitis,” J. Investigative Dermatology, 119(3):609-616 (2002).
Matsuoka et al., “Prostaglandin D2 as a Mediator of Allergic Asthma,” Science, 287(17):2013-2017 (2000).
Monneret et al., “Prostaglandin D2 is a Potent Chemoattractant for Human Eosinophils that Act via a Novel DP Receptor,” J. Exp. Med., 193(2):255-261 (2001).
Munns et al., “Contribution of Type 27 II PLA2 to Prostaglandin Formation: A Study Using a Type II PLA2 Specific Inhibitor SB 203347,” Prostaglandins & Other Lipid Mediators 57:5,6):361-370 (1999).
Romagnani et al., “Cytokines and Chemoattractants in Allergic Inflammation,” Molecular Immunology, 38:881-885 (2001).
Saito et al., “Prostaglandin D2 and Reproduction,” Am. J. of Reproductive Immunology, 47:295-302 (2002).
Fu Zice
Huang Xi Alan
Liu Jiwen
Medina Julio C.
Schmitt Michael J.
Amgen Inc.
Coppins Janet L
Jones Day
Shiao Rei-Tsang
LandOfFree
Asthma and allergic inflammation modulators does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Asthma and allergic inflammation modulators, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Asthma and allergic inflammation modulators will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4063302